KIT Mutations, Melanoma

2002695
copy
 

Copy Utility


emailprint
Example Reports
Detected
Not Detected

Icon

Additional Technical Information
Ordering Recommendation

Detect activating mutations in KIT and PDGFRA. Predict response to tyrosine kinase inhibitor (TKI) therapy. 

Mnemonic
KIT MELAN
Methodology

Massively Parallel Sequencing

Performed

Varies

Reported

10-12 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Tumor tissue.

Specimen Preparation

Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Diff-Quik and Papanicolaou stained cytology smears are also acceptable. Number of slides needed is dependent on the tumor cellularity of the smear. Slide(s) will be destroyed during testing process and will not be returned to client. Protect from excessive heat. Transport block and/or slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.
Resections: Transport 8 unstained 5-micron slides. (Min: 5 slides)
Small Biopsies: Transport 15 unstained 5-micron slides. (Min: 10 slides)

Storage/Transport Temperature

Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.

Unacceptable Conditions

Less than 10 percent tumor. Specimens fixed/processed in heavy metal fixatives. Decalcified specimens. FNA smears with less than 50 tumor cells.

Remarks

Include surgical pathology report.

Stability

Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Reference Interval

By report

Interpretive Data

Refer to report.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note

A full list of the targeted genes and regions is listed in the Additional Technical Information.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
05/20/2019
X
X
X
X
N/A
CPT Codes

81272; 88381; 81314

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
2002148 Block ID 57723-9
2002694 KIT Mutation, Melanoma Interpretation 55201-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • c-KIT
  • CD117 KIT
  • cKIT
  • KIT exons 9, 11,13, 14, 17, and 18
  • TKI resistance
  • TKI sensitivity
KIT Mutations, Melanoma